Knight Diagnostic Laboratories’ expertise in genetics and molecular pathology join together in the diagnosis of inherited cancer syndromes. While most cancer is sporadic, 5-10% of all cancers are inherited. Syndromes may have either recessive or dominant inheritance. Oregon Health and Science University is a center of excellence for Fanconi anemia, a recessive inherited syndrome. Knight Diagnostic Laboratories has been providing comprehensive molecular analyses of the Fanconi genes and other disorders for many years. All inherited cancer syndrome testing is performed and interpreted as described for genetic rare disorders by American College of Medical Genetics.

Showing Results 1 to 10 of 11.

Amniotic Fluid: Full Chromosome Analysis

  • Test Code:
    6020
  • Department:
  • Test Synonyms:
    Chromosome Analysis Amniotic Fluid Full Study Amniotic Fluid AF Amnio
View Test

Blood: High Resolution Chromosome Study reflexed to FISH

View Test

Breakage Analysis: Blood Chromosome Study

View Test

Breakage Analysis: Skin Chromosome Study

View Test

Chorionic Villus Sampling: Full Chromosome Analysis

  • Test Code:
    6100
  • Department:
  • Test Synonyms:
    Chorionic Villus Study CVS Chromosomal Analysis Chromosome Analysis, Chorionic Villi Chorionic Villus Sampling Chromosomes
View Test

Chromosomal Microarray - Postnatal

  • Test Code:
    6500
  • Department:
  • Test Synonyms:
    Array comparative genomic hybridization aCGH Microarray Competitive genomic hybridization Chromosome microarray Postnatal
View Test

Chromosomal Microarray - Prenatal Diagnosis

  • Test Code:
    6510
  • Department:
  • Test Synonyms:
    Array comparative genomic hybridization aCGH Microarray Competitive genomic hybridization Chromosome microarray Prenatal
View Test

Premature Chromatid Separation Analysis

View Test

Sister Chromatid Exchange Analysis

View Test

SNP Microarray – Products of Conception

  • Test Code:
    6550
  • Department:
  • Test Synonyms:
    Array comparative genomic hybridization aCGH Microarray Competitive genomic hybridization Chromosome microarray
View Test

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More